LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity-Reference-Cited by-同舟云学术

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity

Published:2018-04-23 Issue:7 Volume:9 Page:612-617
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Bonday Zahid Q.¹^ORCID,Cortez Guillermo S.¹,Grogan Michael J.¹,Antonysamy Stephen¹,Weichert Ken¹,Bocchinfuso Wayne P.¹,Li Fengling²,Kennedy Steven²,Li Binghui¹,Mader Mary M.¹,Arrowsmith Cheryl H.²³,Brown Peter J.²,Eram Mohammad S.²,Szewczyk Magdalena M.²,Barsyte-Lovejoy Dalia²,Vedadi Masoud²⁴,Guccione Ernesto⁵,Campbell Robert M.¹

Affiliation:

1. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States

2. Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada

3. Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Centre, 101 College Street, MaRS South Tower, Suite 707, Toronto, ON M5G 1L7, Canada

4. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada

5. Institute of Molecular and Cell Biology, Singapore 138673

Funder

Wellcome Trust

Structural Genomics Consortium

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.8b00014

Reference36 articles.